Forecasting the cost of diabetes: A systematic review

Nguyen Linh Viet; Tran Thi Yen Nhi; Vo Ngoc Yen Nhi; Nguyen Thanh Binh; Nguyen Thi Thu Thuy

doi:10.59294/HIUJS.VOL.7.2024.689

Từ khóa:

forecast, cost, diabetes, systematic review

Tóm tắt

Background: Diabetes poses a significant global health risk and is a leading cause of death and reduced life expectancy. Objective: A systematic review was conducted to collect studies predicting the economic burden of diabetes, offering insights for policymakers and stakeholders. Methods: A preferred reporting item for systematic reviews and meta-analyses (PRISMA)-guided systematic review identified relevant studies through a literature search in databases like Embase, PubMed, and Cochrane. Study quality was assessed using the Cost of Illness (COI) checklist. All costs were converted to 2024 US dollars after analyzing study characteristics and findings. Results: There were 16 of 1,667 studies from the three databases satisfied the selection and exclusion criteria. Studies were conducted in several nations across Asia, Europe, North America and globally with all studies were modeled using a descriptive cross-sectional design. Studies have projected the cost of diabetes over a period of 1–40 years. Incidence-based and prevalence-based methods were used in these studies. In previous studies, costs ranged from US$0.19 billion to US$3.1 trillion (USD 2024), depending on the region and forecast year. Incidence-based studies estimated total costs at US$15.88 billion. When combining both approaches, the cost range was found to be between US$0.007 billion and US$248.98 billion. Conclusion: Diabetes is forecast to create a huge economic burden on national health systems, society, and the economy. A concerted effort is required to prepare for such changes. To gain a more holistic understanding of the future costs of diabetes, it is vital to expand the research in developing countries.

Abstract

Background: Diabetes poses a significant global health risk and is a leading cause of death and reduced life expectancy. Objective: A systematic review was conducted to collect studies predicting the economic burden of diabetes, offering insights for policymakers and stakeholders. Methods: A preferred reporting item for systematic reviews and meta-analyses (PRISMA)-guided systematic review identified relevant studies through a literature search in databases like Embase, PubMed, and Cochrane. Study quality was assessed using the Cost of Illness (COI) checklist. All costs were converted to 2024 US dollars after analyzing study characteristics and findings. Results: There were 16 of 1,667 studies from the three databases satisfied the selection and exclusion criteria. Studies were conducted in several nations across Asia, Europe, North America and globally with all studies were modeled using a descriptive cross-sectional design. Studies have projected the cost of diabetes over a period of 1–40 years. Incidence-based and prevalence-based methods were used in these studies. In previous studies, costs ranged from US$0.19 billion to US$3.1 trillion (USD 2024), depending on the region and forecast year. Incidence-based studies estimated total costs at US$15.88 billion. When combining both approaches, the cost range was found to be between US$0.007 billion and US$248.98 billion. Conclusion: Diabetes is forecast to create a huge economic burden on national health systems, society, and the economy. A concerted effort is required to prepare for such changes. To gain a more holistic understanding of the future costs of diabetes, it is vital to expand the research in developing countries.

Tài liệu tham khảo

[1] N. H. Cho, J. E. Shaw,… and B. Malanda, "IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045," (in eng), Diabetes research and clinical practice, vol. 138, pp. 271-281, Apr 2018, doi: 10.1016/j.diabres.2018.02.023.

DOI: https://doi.org/10.1016/j.diabres.2018.02.023

[2] P. Saeedi et al., "Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition," (in eng), Diabetes research and clinical practice, vol. 162, p. 108086, Apr 2020, doi: 10.1016/j.diabres.2020.108086.

[3] C. Bommer, E. Heesemann and S. Vollmer, "The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study," (in eng), Lancet Diabetes Endocrinol, vol. 5, no. 6, pp. 423-430, Jun 2017, doi: 10.1016/s2213-8587(17)30097-9.

DOI: https://doi.org/10.1016/S2213-8587(17)30097-9

[4] R. Williams et al., "Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition," Diabetes research and clinical practice, vol. 162, p. 108072, 2020/04/01/ 2020, doi: https://doi.org/10.1016/j.diabres.2020.108072.

DOI: https://doi.org/10.1016/j.diabres.2020.108072

[5] I. Shemilt, T. James and M. Marcello, "A web-based tool for adjusting costs to a specific target currency and price year," (in English), Evidence & Policy, vol. 6, no. 1, pp. 51-59, 01 Jan. 2010 2010, doi: 10.1332/174426410x482999.

DOI: https://doi.org/10.1332/174426410X482999

[6] L. Schnitzler, T. E. Roberts, L. J. Jackson, A. T. G. Paulus, and S. M. A. A. Evers, "A consensus- based checklist for the critical appraisal of cost-of-illness (COI) studies," International Journal of Technology Assessment in Health Care, vol. 39, no. 1, p. e34, 2023, Art no. e34, doi: 10.1017/S0266462323000193.

DOI: https://doi.org/10.1017/S0266462323000193

[7] J. Hahl, T. Simell,… and O. Simell, "Costs of predicting IDDM," (in eng), Diabetologia, vol. 41, no. 1, pp. 79-85, Jan 1998, doi: 10.1007/s001250050870.

DOI: https://doi.org/10.1007/s001250050870

[8] M. E. Png, J. Yoong,… and H. L. Wee, "Current and future economic burden of diabetes among working-age adults in Asia: conservative estimates for Singapore from 2010-2050," BMC public health, vol. 16, no. 1, pp. 1-9, 2016.

[9] E. S. Huang, A. Basu,… and J. C. Capretta, "Projecting the future diabetes population size and related costs for the U.S," (in eng), Diabetes Care, vol. 32, no. 12, pp. 2225-9, Dec 2009, doi: 10.2337/dc09-0459.

DOI: https://doi.org/10.2337/dc09-0459

[10] R. Waldeyer, R. Brinks,… and A. Icks, "Projection of the burden of type 2 diabetes mellitus in Germany: a demographic modelling approach to estimate the direct medical excess costs from 2010 to 2040," Diabetic medicine, vol. 30, no. 8, pp. 999-1008, 2013.

DOI: https://doi.org/10.1111/dme.12177

[11] S. Flessa and A. Zembok, "Costing of diabetes mellitus type II in Cambodia," (in eng), Health Econ Rev, vol. 4, no. 1, p. 24, Dec 2014, doi: 10.1186/s13561-014-0024-4.

DOI: https://doi.org/10.1186/s13561-014-0024-4

[12] M. Javanbakht, A. Mashayekhi,… and A. Afshin, "Projection of diabetes population size and associated economic burden through 2030 in Iran: evidence from micro-simulation Markov model and Bayesian meta-analysis," PloS one, vol. 10, no. 7, p. e0132505, 2015.

DOI: https://doi.org/10.1371/journal.pone.0132505

[13] M. E. Png, J. Yoong,… and H. L. Wee, "Current and future economic burden of diabetes among working-age adults in Asia: conservative estimates for Singapore from 2010-2050," (in eng), BMC Public Health, vol. 16, p. 153, Feb 16 2016, doi: 10.1186/s12889-016-2827-1.

DOI: https://doi.org/10.1186/s12889-016-2827-1

[14] J. C. Lauffenburger, M. Mahesri and N. K. Choudhry, "Not there yet: using data-driven methods to predict who becomes costly among low-cost patients with type 2 diabetes," BMC Endocrine Disorders, vol. 20, no. 1, p. 125, 2020/08/17 2020, doi: 10.1186/s12902-020-00609- 1.

DOI: https://doi.org/10.1186/s12902-020-00609-1

[15] B. Anja and R. Laura, "The cost of diabetes in Canada over 10 years: applying attributable health care costs to a diabetes incidence prediction model," Health promotion and chronic disease prevention in Canada: research, policy and practice, vol. 37, no. 2, p. 49, 2017.

DOI: https://doi.org/10.24095/hpcdp.37.2.03

[16] C. Bommer et al., "Global economic burden of diabetes in adults: projections from 2015 to 2030," Diabetes care, vol. 41, no. 5, pp. 963-970, 2018.

DOI: https://doi.org/10.2337/dc17-1962

[17] U. H. Panton, M. Bagger, and S. Barquera, "Projected diabetes prevalence and related costs in three North American urban centres (2015–2040)," Public Health, vol. 157, pp. 43-49, 2018.

DOI: https://doi.org/10.1016/j.puhe.2017.12.023

[18] S. Khanal, L. Veerman, L. Nissen, and S. Hollingworth, "Forecasting the amount and cost of medicine to treat type 2 diabetes mellitus in Nepal using knowledge on medicine usage from a developed country," Journal of Pharmaceutical Health Services Research, vol. 10, no. 1, pp. 91-99, 2019, doi: https://doi.org/10.1111/jphs.12265.

DOI: https://doi.org/10.1111/jphs.12265

[19] D. Zhu, D. Zhou, N. Li, and B. Han, "Predicting Diabetes and Estimating Its Economic Burden in China Using Autoregressive Integrated Moving Average Model," (in eng), Int J Public Health, vol. 66, p. 1604449, 2021, doi: 10.3389/ijph.2021.1604449.

DOI: https://doi.org/10.3389/ijph.2021.1604449

[20] J. Liu et al., "Projected rapid growth in diabetes disease burden and economic burden in China: a spatio-temporal study from 2020 to 2030," (in eng), Lancet Reg Health West Pac, vol. 33, p. 100700, Apr 2023, doi: 10.1016/j.lanwpc.2023.100700.

DOI: https://doi.org/10.1016/j.lanwpc.2023.100700

[21] N. M. Abu-Rmeileh, R. Ghandour, A. Mataria, S. Awawda, S. Jabr, and M. O'Flaherty, "Time to act on diabetes mellitus prevention in the West Bank, oPt: Current and future direct cost of diabetes and its complications," Obesity Medicine, vol. 6, pp. 18-22, 2017.

DOI: https://doi.org/10.1016/j.obmed.2017.04.001

[22] Population Review World. https://worldpopulationreview.com/countries (accessed 2024).